Skip to main content

Share story

Science

IBM (IBM) Stock Slides Despite Quantum Computing Breakthrough with Algorithmiq

IBM (IBM) Stock Slides Despite Quantum Computing Breakthrough with Algorithmiq Image: Primary
IBM shares fell 1.98% to close at $221.96 on Tuesday despite Algorithmiq announcing a quantum computing achievement using IBM's Heron processor. Algorithmiq said the collaboration successfully simulated heterogeneous quantum matter beyond the capabilities of classical computers. The experiment modeled information propagation across regions with distinct quantum characteristics, mimicking patterns found in industrial catalysts and battery materials. No classical computational approach has produced consistent results across the full tested parameters since the challenge was published eight months ago. Researchers validated the quantum outputs by systematically varying noise characteristics and recalibrating gate operations across multiple IBM processors, finding the quantum results remained consistent. Algorithmiq also released monoprop, an open-source software package for classical computation of molecular ground states, to enable independent verification of quantum advantage claims. The tool allows researchers to scrutinize published findings using standardized methods. IBM has invested heavily in quantum processor development and collaborative research over multiple years. The stock decline indicated the technical milestone did not offset broader market selling pressure.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from blockonomi.com and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
AI Science
AI Science

Insilico says AI-discovered Rentosertib has entered Phase III trials

Insilico Medicine says Rentosertib, its generative AI-discovered drug candidate also known as ISM001-055, has entered Phase III clinical trials for idiopathic pulmonary fibrosis. The company described the clinical advance in an announcement carried by News-Medical.Net.

Infrastructure Science
Infrastructure Science

Quilty Space projects shortfall of about 150 launches through 2030

The world outside China faces a shortfall of about 150 rocket launches through 2030 against demand from satellite operators and civil space agencies, analytics firm Quilty Space estimates in a new report.

Science Products
Science Products

PopVax offers personalized cancer vaccine manufacturing at expected $300,000 cost

PopVax's RNA Foundry is offering contract development and manufacturing of personalized cancer vaccine candidates at its Hyderabad facility. The company expects most projects to cost around $300,000 and take 8-10 weeks, depending on manufacturing slot availability.